Business Wire

IDEMIA Invests Further in APAC Border Processing Capability Platform

Share

Building on its recently renewed business in the region, IDEMIA is expanding its investment in its people in Canberra and Sydney.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190924006086/en/

(Photo: Business Wire)

(Photo: Business Wire)

The growing organization is driven by the adaptation of the Gen 3.0 Border & Airport platform for the local market with a portfolio of solutions for a seamless traveller experience across the whole Border and Airport process.

The teams are placed as close as possible to customer operations to foster innovation and incubate new concepts, whilst being part of IDEMIA’s global innovation community and benefiting from its worldwide and multi-sectorial research and development capacity.

This leading edge passenger facilitation capability was refined and productised for scalability through IDEMIA’s work with the award winning Singapore Changi airport in Terminals 3 and 4 and is now being further adapted to the other markets in Asia Pacific.

The Gen 3.0 platform is built on IDEMIA’s world leading technology in contactless biometrics: a highly scalable and industrial biometric engine and on the move to contactless sensors for Face, Iris and Fingerprint recognition. It is a proven and ready to deliver on a vision of contactless passenger processing at the airport.

The suite includes an innovative walkthrough eGate, designed for the free flow of passengers while guaranteeing they are seen, recognised and cleared by authorities. The new solution is also designed to alleviate some of the pressures on authorities where most legitimate travellers will be processed in self service and Officers will intervene by exception, being empowered by mobile-based business applications allowing Officers to operate while roaming the airport floor.

A significant part of the suite is already deployed in airports across Asia Pacific and with the additional investment in its Australian footprint IDEMIA will reinforce further its capacity to deliver.

Tim Ferris, IDEMIA’s President for Asia Pacific Region, said: “The Asia Pacific region is at the forefront of Border & Airport innovation and it remains a strategic growth market for IDEMIA. Through the expansion of our capacity in Australia, we will better support our customers in the region and continue the development of a very successful suite of products and solutions for the global markets”

About IDEMIA

IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.

Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors.

With 13,000 employees around the world, IDEMIA serves clients in 180 countries.

For more information, visit www.idemia.com / Follow @IdemiaGroup on Twitter

Contact information

Uma Kanapathy
idemia@redhill.asia

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Post Malone and Crocs Launch Fourth Collaboration9.12.2019 20:57:00 EETPress release

Crocs, Inc. (NASDAQ: CROX), a global leader in innovative, casual footwear for women, men and children, today announced their latest product collaboration with multi-platinum recording artist Post Malone. This ground-breaking fourth installment of the Post Malone x Crocs collaboration series features the Post Malone x Crocs Duet Max Clog, an innovative clog silhouette with a unique blue and black urban camo pattern, an exaggerated chunky outsole and pivotable backstraps with adjustable hook and loop closures. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191209005664/en/ The Post Malone x Crocs Duet Max Clog is an innovative clog silhouette with a unique blue and black urban camo pattern, an exaggerated chunky outsole and pivotable backstraps with adjustable hook and loop closures. This is the fourth collaboration between the duo. (Photo: Business Wire) The evolution of the Post Malone x Crocs partnership is evident over th

Knopp Biosciences Presents Data Further Characterizing Its Lead Kv7.2 Activator Drug Candidate for the Treatment of KCNQ2 Epileptic Encephalopathy at the American Epilepsy Society’s 2019 Annual Meeting9.12.2019 20:00:00 EETPress release

Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases with high unmet need, today presented data characterizing KB-3061, the lead molecule in the Company’s Kv7 ion channel platform, at the American Epilepsy Society’s (AES) 2019 Annual Meeting in Baltimore, Maryland. Knopp is advancing the development of KB-3061 as a potential precision medicine treatment for the rare, neonatal disease KCNQ2 epileptic encephalopathy (KCNQ2-EE), a genetically defined disease associated with seizures beginning in the first days of life and profound neurodevelopmental delay. The disease is caused by dominant-negative mutations in the KCNQ2 gene, which produces a potassium channel, Kv7.2, critical to early brain development. Data presented at AES by Knopp scientists and its academic collaborators support the continued development of KB-3061 as a potential treatment for children with KCNQ2-EE. K

Murray Energy Corporation Posts Information to its Website Related to Murray Metallurgical9.12.2019 18:46:00 EETPress release

Beginning on December 2, 2019, Murray Energy Corporation (the “Company”) engaged in confidential discussions under separate confidentiality agreements with certain members of an ad hoc group of superpriority lenders related Murray Metallurgical Coal Holdings, LLC and its subsidiaries (collectively, “Murray Metallurgical”). The confidentiality agreements require the Company to publicly disclose all material non-public information provided to such lenders on or prior to 8:30am (New York time) on December 9, 2019. The Company has posted certain previously undisclosed material to its website to satisfy its disclosure obligations under the confidentiality agreements. Such information can be viewed at the Investors portion of the Company’s website, located at murrayenergycorp.com/investors. Further inquiries should be directed to media@coalsource.com. Safe Harbor Statement The materials referenced in this release and posted to our website include forward-looking statements. A variety of fact

Seattle Genetics and Takeda Announce Additional Analyses of ADCETRIS® (Brentuximab Vedotin) ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials at the 2019 ASH Annual Meeting9.12.2019 18:00:00 EETPress release

Seattle Genetics, Inc. (Nasdaq:SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced additional analyses of results from the ECHELON-1 and ECHELON-2 frontline phase 3 trials of ADCETRIS® (brentuximab vedotin). These analyses were presented at the 61st Annual Meeting of the American Society of Hematology (ASH) taking place December 7-10, 2019 in Orlando, Fla. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of classical Hodgkin lymphoma and expressed on the surface of several types of peripheral T-cell lymphomas (PTCL). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191209005169/en/ The ECHELON-1 analysis highlighted a four-year update of the phase 3 clinical trial in a poster presentation. ECHELON-1 is evaluating ADCETRIS in combination with AVD (Adriamycin [doxorubicin], vinblastine and dacarbazine) compared to ABVD (Adriamycin [doxorubicin], bleomycin, vinblasti

Takeda Demonstrates Its Long-Standing Commitment to Advancing Treatments for Rare Bleeding Disorders with Studies Highlighting Real-World Evidence and Investigational Gene Therapy at ASH 20199.12.2019 18:00:00 EETPress release

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”), today presented nine hematology poster presentations at the 61st American Society of Hematology (ASH) Annual Meeting that underscore its commitment to advancing treatments for rare bleeding disorders by incorporating real-world data and developing innovative adeno-associated virus (AAV) gene therapies. Understanding Real-World Evidence to Advance Patient-Centric Innovation in Bleeding Disorders Real-world evidence from studies across many of Takeda’s portfolio of treatments for hemophilia demonstrate the cost savings and patient benefits resulting from ongoing personalized treatment. However, in von Willebrand disease, real-world evidence highlights the ongoing unmet clinical need for personalization, as it may enable improved treatment outcomes. Insights presented at ASH include: ADYNOVATE ® [Antihemophilic Factor (Recombinant), PEGylated]: In the poster “Real-World Age-Stratified FVIII Consumption and Bleed Outcom

Altasciences to Conduct Clinical Trial for Opioid Use Disorder Under NIH Funding9.12.2019 17:39:00 EETPress release

Altasciences has been selected by Indivior PLC to conduct "A Phase I, Double-Blind, Placebo-Controlled, Randomized, Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of INDV-2000 (C4X_3256) Under Fasting and Fed Conditions in Healthy Volunteers", pursuant to the National Institutes of Health (NIH) Funding Opportunity Announcement RFA-DA-19-002, dedicated to the development of medications to prevent and treat opioid use disorder and overdose. The grant was made to Indivior by the NIH in fiscal year 2019, to apply scientific solutions to reverse the national opioid crisis. In March 2018, Indivior entered into a license agreement with C4X Discovery Holdings PLC (C4X) whereby Indivior obtained exclusive global rights to develop and commercialize INDV-2000 (C4X_3256). The first-in-human, single-ascending-dose study will be conducted in two parts — Part I: double-blind, placebo-controlled, randomized, single-ascending-dose study in fasted condition. Part II:

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom